이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Immunome 과거 수익 실적

과거 기준 확인 0/6

Immunome의 수입은 연평균 -60.7%의 비율로 감소해 온 반면, Biotechs 산업은 수입이 연평균 15.5%의 비율로 증가했습니다. 매출은 연평균 131.8%의 비율로 증가해 왔습니다.

주요 정보

-60.7%

수익 성장률

29.7%

EPS 성장률

Biotechs 산업 성장	17.0%
매출 성장률	131.8%
자기자본 수익률	-81.3%
순이익	-1,829.4%
최근 수익 업데이트	31 Mar 2024

최근 과거 실적 업데이트

업데이트 없음

Recent updates

수익 및 비용 분석

Immunome 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

NasdaqCM:IMNM 수익, 비용 및 수입 (USD Millions )
날짜	수익	수익	G+A 비용	R&D 비용
31 Mar 24	13	-232	23	0
31 Dec 23	14	-107	20	0
30 Sep 23	10	-22	15	0
30 Jun 23	7	-27	14	0
31 Mar 23	2	-30	13	0
31 Dec 22	0	-38	14	0
30 Sep 22	0	-38	14	4
30 Jun 22	0	-36	13	9
31 Mar 22	0	-32	13	12
31 Dec 21	0	-25	11	14
30 Sep 21	0	-21	10	12
30 Jun 21	0	-22	8	9
31 Mar 21	0	-19	6	7
31 Dec 20	0	-18	5	7
30 Sep 20	0	-17	3	8
30 Jun 20	0	-11	2	9
31 Mar 20	0	-11	2	9
31 Dec 19	0	-10	2	9

양질의 수익: IMNM 은(는) 현재 수익성이 없습니다.

이익 마진 증가: IMNM 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: IMNM 은(는) 수익성이 없으며 지난 5년 동안 연간 60.7% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 IMNM 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: IMNM 은(는) 수익성이 없어 지난 해 수익 성장을 Biotechs 업계( -14.4% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: IMNM 현재 수익성이 없기 때문에 마이너스 자본 수익률( -81.25% )을 갖습니다.

Immunome 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

Recent updates

Immunome, Inc. Appoints Phil Tsai as Chief Technical Officer

President recently bought US$1.4m worth of stock

Consensus EPS estimates fall by 97%, revenue upgraded

Immunome, Inc. (NasdaqCM:IMNM) completed the acquisition of Substantially all Assets of Atreca, Inc. (NasdaqGS:BCEL).

Immunome, Inc. Announces Promotion of Max Rosett to Chief Financial Officer

Immunome, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

Immunome, Inc. Appoints Kinney Horn as Chief Business Officer

Immunome, Inc., Annual General Meeting, Jun 12, 2024

Immunome, Inc. Appoints Sandra M. Swain to Board of Directors

Consensus EPS estimates fall by 17%

Immunome, Inc. (NasdaqCM:IMNM) completed the acquisition of Assets from Ayala Pharmaceuticals, Inc. (OTCPK:ADXS).

Immunome, Inc. has completed a Follow-on Equity Offering in the amount of $200 million.

Immunome, Inc. has completed a Follow-on Equity Offering in the amount of $200 million.

New minor risk - Share price stability

Immunome, Inc. Announces Promotion of Max Rosett to Executive Vice President, Operations

Consensus EPS estimates upgraded to US$0.97 loss

Immunome: Why It Has Doubled Over The Last Month

Immunome Appoints Phil Roberts as Chief Technical Officer

Immunome, Inc. Announces Board Changes

Immunome, Inc. Announces Executive Changes, Effective January 2, 2024

Immunome, Inc. announced that it has received $124.722508 million in funding from Enavate Sciences, EcoR1 Capital, LLC, Redmile Group, LLC, Janus Henderson Group plc, Avidity Partners Management, L.P., Woodline Partners LP and other investors

Immunome, Inc. Appoints Jean-Jacques Bienaimé to Board of Directors

Immunome Appoints Bob Lechleider as Chief Medical Officer

Less than half of directors are independent

New major risk - Shareholder dilution

Immunome, Inc. (NasdaqCM:IMNM) entered into an agreement to acquire MorphImmune, Inc. from Research Bridge Partners, Investment Arm and others for $51.7 million.

Immunome, Inc. announced that it expects to receive $124.722508 million in funding

No longer forecast to breakeven

Will Immunome (NASDAQ:IMNM) Spend Its Cash Wisely?

Immunome, Inc. Announces Formation of Antibody-Drug Conjugate and T Cell Redirection Advisory Board

Is Immunome (NASDAQ:IMNM) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$8.50

High number of new directors

Immunome Presents Preclinical Data on Novel Anti-EPN1 Antibody IMM20059 at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

Forecast to breakeven in 2024

Immunome Announces Publication in Clinical & Translational Immunology Highlighting B Cell Repertoires in Patients with Breast Cancer

Immunome GAAP EPS of -$0.74

Here's Why We're Watching Immunome's (NASDAQ:IMNM) Cash Burn Situation

Immunome, Inc.’S Covid-19 Cocktail Retains Neutralizing Activity Against the Most Prevalent Omicron Subvariants in the Us, Ba.4/5 and Ba.2.12.1

Immunome gains 34% after preclinical data on COVID-19 antibody

Immunome, Inc. Announces Initiation of Phase 1b Study of IMM-BCP-01 for the Treatment of COVID-19

Immunome, Inc. Provides Research & Development Update on Lead Oncology Candidate Targeting IL-38

Immunome, Inc. Announces Data Demonstrating COVID-19 Antibody Cocktail Potently Clears Omicron BA.1 Variant in Hamster Model and Retains Activity Against BA.2 Subvariant

Immunome, Inc., Annual General Meeting, Jun 15, 2022

High number of new and inexperienced directors

Price target increased to US$33.00

We Think Immunome (NASDAQ:IMNM) Can Afford To Drive Business Growth

Immunome, Inc. Antibody Cocktail Effective Against SARS-CoV-2 Omicron Variant in Vitro Live Virus Testing

Immunome Provides Update on Investigational New Drug Application for IMM-BCP-01 for the Treatment of COVID-19

Immunome, Inc. Expects IMM-BCP-01 Antibody Cocktail to Neutralize the SARS-CoV-2 Omicron Variant

Immunome Announces Submission of Investigational New Drug (IND) Application for IMM-BCP-01 for the Treatment of COVID-19

Companies Like Immunome (NASDAQ:IMNM) Are In A Position To Invest In Growth

Immunome, Inc.(NasdaqCM:IMNM) dropped from Russell 3000E Growth Index

Director recently bought US$248k worth of stock

Immunome SARS-CoV-2 Antibody Cocktail Neutralizes UK, South Africa, Brazil and California Variants in Preclinical Testing; Progressing Towards IND Filing

Immunome launches $27M private placement

Do Institutions Own Immunome, Inc. (NASDAQ:IMNM) Shares?

Immunome, Inc. Discovers Antibodies Capable of Neutralizing Multiple SARS-CoV-2 Variants, Including the South African Variant, in Pseudovirus Testing

New 90-day high: US$39.01

Abzena Selects Immunome, Inc.’s Partner Research Organization for IMM-BCP-01

New 90-day high: US$20.24

Read This Before Selling Immunome, Inc. (NASDAQ:IMNM) Shares

New 90-day high: US$13.73

Immunome, Inc. Appoints Diane Marcou as Interim Chief Financial Officer

Immunome EPS misses by $7.22

Key Executive recently bought US$1m worth of stock

Immunome, Inc. has completed an IPO in the amount of $39 million.

수익 및 비용 분석

수익 및 매출 내역

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

자기자본 수익률

자산 수익률

고용 자본 수익률

과거 성과가 우수한 기업 찾기